Format

Send to

Choose Destination
See comment in PubMed Commons below
J Clin Invest. 2014 Jan;124(1):30-9. doi: 10.1172/JCI69738. Epub 2014 Jan 2.

New and emerging HDAC inhibitors for cancer treatment.

Abstract

Epigenetic enzymes are often dysregulated in human tumors through mutation, altered expression, or inappropriate recruitment to certain loci. The identification of these enzymes and their partner proteins has driven the rapid development of small-molecule inhibitors that target the cancer epigenome. Herein, we discuss the influence of aberrantly regulated histone deacetylases (HDACs) in tumorigenesis. We examine HDAC inhibitors (HDACis) targeting class I, II, and IV HDACs that are currently under development for use as anticancer agents following the FDA approval of two HDACis, vorinostat and romidepsin.

PMID:
24382387
PMCID:
PMC3871231
DOI:
10.1172/JCI69738
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Journal of Clinical Investigation Icon for PubMed Central
    Loading ...
    Support Center